Forma Therapeutics Holdings Inc. (FMTX): Price and Financial Metrics

Forma Therapeutics Holdings Inc. (FMTX): $20.01

0.03 (+0.15%)

POWR Rating

Component Grades













Add FMTX to Watchlist
Sign Up

Industry: Biotech



in industry

FMTX Stock Price Chart Interactive Chart >

Price chart for FMTX

FMTX Price/Volume Stats

Current price $20.01 52-week high $20.68
Prev. close $19.98 52-week low $4.95
Day low $19.98 Volume 739,100
Day high $20.01 Avg. volume 847,595
50-day MA $16.65 Dividend yield N/A
200-day MA $10.81 Market Cap 957.54M

Forma Therapeutics Holdings Inc. (FMTX) Company Bio

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

FMTX Latest News Stream

Event/Time News Detail
Loading, please wait...

FMTX Latest Social Stream

Loading social stream, please wait...

View Full FMTX Social Stream

Latest FMTX News From Around the Web

Below are the latest news stories about FORMA THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate FMTX as an investment opportunity.

Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease

HANOVER, MD and WATERTOWN, Mass., September 30, 2022--Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease

Yahoo | September 30, 2022

Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More

Regulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week.

Yahoo | September 7, 2022

Novo Nordisk (NVO) to Tap Into SCD Space With Forma Acquisition

Novo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space.

Yahoo | September 2, 2022

Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition News

There's a major pharmaceutical market deal afoot -- and it's worth over $1 billion -- so FMTX stock is heading higher on the news.

David Moadel on InvestorPlace | September 1, 2022

Guardforce AI (GFAI) Stock Gets a Boost From New Exec Team

Guardforce AI (GFAI) stock is climbing higher on Thursday after announcing a new executive team that will lead the company.

William White on InvestorPlace | September 1, 2022

Read More 'FMTX' Stories Here

FMTX Price Returns

1-mo N/A
3-mo N/A
6-mo 141.67%
1-year 82.91%
3-year N/A
5-year N/A
2022 0.00%
2021 -59.26%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7068 seconds.